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in young patients with acute pulmonary embolism (pe), the predictive value of currently available 
prognostic tools has not been evaluated. Our objective was to compare prognostic value of 7 available 
tools (GpS, peSi, speSi, prognostic Algorithm, pRep, shock index and Riete) in patients aged <50 
years. We used the RIETE database, including PE patients from 2001 to 2017. The major outcome was 
30-day all-cause mortality. Of 34,651 patients with acute PE, 5,822 (17%) were aged <50 years. Of 
these, 83 (1.4%) died during the first 30 days. Number of patients deemed low risk with tools was: PREP 
(95.9%), GPS (89.6%), PESI (87.2%), Shock index (70.9%), sPESI (59.4%), Prognostic algorithm (58%) 
and RIETE score (48.6%). The tools with a highest sensitivity were: Prognostic Algorithm (91.6%; 95% 
CI: 85.6–97.5), RIETE score (90.4%; 95%CI: 84.0–96.7) and sPESI (88%; 95% CI: 81–95). The RIETE, 
prognostic Algorithm and speSi scores obtained the highest overall sensitivity estimates for also 
predicting 7- and 90-day all-cause mortality, 30-day PE-related mortality, 30-day major bleeding and 
30-day VTE recurrences. The proportion of low-risk patients who died within the first 30 days was lowest 
using the Prognostic Algorithm (0.2%), RIETE (0.3%) or sPESI (0.3%) scores. In PE patients less 50 years, 
30-day mortality was low. Although sPESI, RIETE and Prognostic Algorithm scores were the most 
sensitive tools to identify patients at low risk to die, other tools should be evaluated in this population 
to obtain more efficient results.
The incidence and severity of acute pulmonary embolism (PE) progressively increase with patient’s age1–3. In the 
elderly, PE generally develops in patients with impaired mobility and a number of co-morbidities or the use of 
concomitant drugs4–6. In young individuals, PE frequently affects women with hormonal alterations (including 
pregnancy or use of contraceptives), with minor co-morbidities, or in presence thrombophilia4–8. Unfortunately, 
data on the clinical presentation, treatment, and outcomes during the course of anticoagulation in young patients 
with PE remain scarce. Although mortality in this population is low, the impact in terms of avoidable deaths and 
complications is relevant. Further, it remains unclear whether the widely available risk prediction tools (e.g., PESI, 
sPESI, and others) – primarily validated in older patients with a high burden of co-morbidities – do perform well 
in the young9.
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In the Emergency wards, prognostic tools are commonly used to classify patients with PE into high-, medium- 
or low-risk categories, aimed at selecting the most appropriate management strategy at the individual level. 
However, a number of systematic reviews of prognostic models showed inconsistent results across the studies10–14. 
In 2016, a systematic review and meta-analysis provided evidence-based information on the validity and utility of 
several prognostic tools9, although their performances in patients aged <50 years remains unclear.
The most severe short-term complication of PE is 30-day all-cause death. The RIETE (Registro Informatizado 
Enfermedad TromboEmbólica) registry was established in Spain in 2001. It is an ongoing, multicenter, inter-
national observational registry of consecutive patients with objectively confirmed venous thromboembolism 
(VTE)15. The aim of this study was to compare seven currently available prognostic tools in terms of their ability 
to identify low-risk patients with acute PE aged <50 years.
Methods
Study design. We retrospectively compared seven different prognosis tools in patients aged <50 years with 
no-high risk acute PE. The major outcome measure was 30-day all-cause mortality. Secondary outcomes included 
7-day and 90-day all-cause mortality as well as the 30-day PE-related mortality, major bleeding, and VTE recur-
rences rates.
inclusion criteria. Patients included in the RIETE registry we deemed eligible in presence of acute symp-
tomatic PE confirmed by objective testing (pulmonary angiography, ventilation-perfusion lung scintigraphy or 
helical computed tomography scan). Patients were excluded if they were currently participating in a therapeutic 
clinical trial with a blinded study drug. The methodology of RIETE has been previously published15. Data were 
recorded from each participating hospital and submitted to a coordinating center through a secure website. Each 
patient was assigned with a unique identification number to maintain patient confidentiality, and data quality was 
regularly monitored electronically. Patients received anticoagulant treatment according to current guidelines16–18. 
All patients provided oral or written informed consent to be included in the registry, according to the require-
ments of ethics committees within each hospital (Authorization of clinical research ethics committee Germans 
Trias i Pujol and Institut Catalá de la Salud, 05122006). Researchers assessed mortality by using patient or proxy 
interviews and/or through review of hospital clinical records. In case of death, we performed a thorough review 
of medical records (accompanied by proxy interviews when necessary) to clarify the date and cause of death. 
Investigators were instructed to classify a death as due to PE in the following cases: 1) PE-related death con-
firmed on necropsy or 2) death following a clinically severe PE event (either initially or shortly after an objectively 
confirmed recurrent event) in the absence of any alternative diagnosis. Major bleeding was defined as bleeding 
occurring at high-risk anatomic locations (intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, 
pericardial, or intramuscular bleeding with compartment syndrome), or overt bleeding requiring a transfusion 
of two or more units of packed red blood cells. Confirmation of recurrent PE was documented by evidence of a 
novel intraluminal filling defect on CT, enlargement of a previous filling defect on CT, or evidence of a new per-
fusion scan defect involving >75% of a lung segment.
Study variables and definitions. The following parameters are recorded in RIETE: patient’s baseline char-
acteristics; clinical status (including any coexisting or underlying conditions such as chronic heart or lung dis-
ease), recent major bleedings; presence of anemia; creatinine levels; risk factors for PE; treatment received upon 
PE diagnosis; therapeutic outcomes; and risk factors for PE according to the ISTH criteria19. Recent bleeding was 
considered to be present in subjects who suffered a major bleeding <30 days before PE.
prognostic tools. Comparison of prognostic tools was performed through discrimination20,21. In accordance 
with the current guidelines22,23, the tools aimed at identifying low-risk PE patients were evaluated according to 
their sensitivity. The following prognostic tools were investigated: Geneva prognostic score (GPS)24, Pulmonary 
Embolism Severity Index (PESI)25, simplified PESI (sPESI)26, Prognostic Algorithm27, Facteurs PRonostiques 
dans l’Embolie Pulmonaire (PREP)28, shock index29, and RIETE score30. The prognostic tools are depicted in 
detail in Supplement Table 1.
follow-up. Patients were managed according to the clinical practice of each participating hospital and were 
not subjected to any predetermined intervention. For the study purpose of the study and in light of the primary 
outcome measure, patients were followed up for a minimum of 30 days. In addition, data at 90 days were collected 
for analyzing the secondary outcome. During follow-up, special attention was paid to any signs or symptoms 
suggestive of recurrent PE or bleeding complications. Each episode of suspected recurrent deep vein thrombosis 
(DVT) or PE required documented objective imaging findings. Most outcomes were classified as reported by the 
participating centers. However, a central adjudicating committee reviewed all outcomes reported as uncertain 
(less than 10% of all events).
Statistical analysis. A descriptive analysis was performed using relative frequencies for categorical variables 
and means (SD) for continuous variables. We used the Student’s t-test and the χ2 test (or Fisher’s exact test where 
appropriate) to compare continuous or categorical variables, respectively. The 95% confidence interval (CI) for 
proportions was calculated using the Clopper-Pearson exact method. The discrimination of models was evalu-
ated by the degree to which they distinguished between subjects who reached the outcome versus those who did 
not. We used the area under curve (AUC) and determined the percentage of patients deemed to be at low-risk. 
We assessed sensitivity, specificity, positive and negative predictive values. All calculations were performed with 
the SPSS statistical software, version 20 (IBM, Armonk, NY, USA). Two-sided p values < 0.05 were considered 
statistically significant.
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Results
Of the 34,651 patients with acute PE enrolled in RIETE by August 2017, 5,822 (17%) were aged <50 years (Fig. 1). 
Patients aged <50 years were less likely to have concomitant diseases (Table 1). Moreover, they had a higher like-
lihood to have chest pain or tachycardia at baseline and a lower likelihood to present with syncope, hypoxemia, 
raised troponin levels, atrial fibrillation, right bundle branch block on the electrocardiogram, right ventricle dys-
function or raised pulmonary artery pressure levels on the echocardiogram. Finally, patients aged <50 years were 
more likely to score at low-risk according to PESI or sPESI. Eight of the 5,822 patients (0.14%) did not receive 
anticoagulant therapy. Of them, five did not start anticoagulation because they died on the same day of PE diag-
nosis. Three cases underwent inferior vena cava filter placement because of contraindications to anticoagulation.
Overall, 38 patients aged <50 years (0.65%; 95% CI: 0.46–0.89%) died within the first 7 days, 83 (1.43%; 
95% CI: 1.14–1.76%) within the first 30 days, and 148 (2.54%; 95% CI: 2.15–2.98%) within the first 90 days. The 
most common causes of death at 30 days were pulmonary embolism (39.7%) and disseminated cancer (32.4%). 
Moreover, 45 patients (0.77%) developed major bleeding and 63 (1.08%) had VTE recurrences within the first 30 
days (55.5% recurred as PE and 44.5% as DVT).
30-day all-cause mortality. The proportion of patients considered to be at low risk was highest using 
the PREP (95.9%), GPS (89.6%) or PESI (87.2%) scores, whereas the proportion of low-risk patients who died 
within the first 30 days was lowest using the Prognostic Algorithm (0.2%), RIETE (0.3%), or sPESI (0.3%) scores 
(Table 2). The highest sensitivity was obtained using the Prognostic Algorithm (91.6%; 95% CI: 85.6–97.5%), 
RIETE (90.4%; 95% CI: 84–96.7%), or sPESI scores (88%; 95% CI: 81–95%; Table 3). All prognostic tools had an 
excellent negative predictive value. The tools that performed better in terms of specificity were PREP (96.2%; 95% 
CI: 95.7–96.7%), GPS (90.2%; 95% CI: 89.4–90.9%), and PESI (87.8%; 95% CI: 87–88.7%).
7- and 90-day all-cause mortality and other outcomes. With regard to the prediction of 30-day 
PE-related mortality, the highest sensitivity estimates were obtained using the Prognostic Algorithm (90.3%; 95% 
CI: 79.9–100%), RIETE score (87.1%; 95% CI: 75.3–98.9%), and sPESI (83.8%; 95% CI: 70.9–96.8%; Table 4). 
As far as major bleeding is concerned, the highest sensitivity estimates were obtained using the RIETE (73.3%; 
95%CI: 60.4–86.3%), Prognostic Algorithm (66.7%; 95% CI: 52.9–80.4%), and sPESI scores (64.4%; 95% CI: 
Figure 1. Flow diagram.
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50.5–78.4%). With regard to VTE recurrences, the highest sensitivity estimates were obtained using the RIETE 
(68.3%; 95% CI: 56.8–79.8%), Prognostic Algorithm (66.7%; 95% CI: 55–78.3%), and sPESI scores (65.1%; 95% 
CI: 53.3–76.9%). For 7- or 90-day all-cause mortality, 30-day major bleeding and 30-day VTE recurrences, the 
highest sensitivity estimates were obtained using the RIETE, Prognostic Algorithm, and sPESI scores (Table 5).
<50 years ≥50 years
Patients, N 5,822 28,829
Clinical characteristics,
Male sex 2,855 (49%) 13,304 (46%)
Body weight, kg/m2 80 ± 20 75 ± 15
Body mass index > 30 kg/m2 (N = 23,605) 1,217 (29%) 6,020 (31%)
Underlying diseases,
Chronic lung disease 224 (3.8%) 4,716 (16%)
Chronic heart failure 70 (1.2%) 3,117 (11%)
Recent major bleeding 129 (2.2%) 684 (2.4%)
Risk factors,
Active cancer 608 (10%) 7,110 (25%)
Recent surgery 916 (16%) 3,200 (11%)
Recent immobility ≥ 4 days 925 (16%) 6,476 (22%)
Pregnancy or postpartum 297 (5.1%) 11 (0.04%)
Oestrogen use 1,400 (24%) 460 (1.6%)
Recent travel 275 (4.7%) 598 (2.1%)
None of the above (unprovoked) 2,176 (37%) 13,752 (48%)
Prior VTE 696 (12%) 4,413 (15%)
Signs or symptoms,
Dyspnea 4,242 (73%) 23,591 (82%)
Chest pain 3,866 (66%) 12,128 (42%)
Syncope 652 (11%) 4,418 (15%)
Abnormal mental status 90 (1.5%) 1,433 (5.0%)
Heart rate ≥ 110 bpm 1,394 (24%) 5,639 (20%)
SBP levels < 100 mm Hg 463 (8.0%) 2,326 (8.1%)
Respiratory rate > 30 pm (N = 11,555) 140 (6.8%) 860 (9.1%)
Temperature < 36 °C 116 (2.0%) 1,008 (3.5%)
Sat O2 levels < 90% (N = 21,796) 503 (16%) 5,961 (32%)
Electrocardiogram,
Yes 4,747 (82%) 24,988 (87%)
Atrial fibrillation 35 (0.74%) 2,473 (9.9%)
Right bundle branch block 526 (11%) 4,491 (18%)
Echocardiogram,
Yes 2,808 (48%) 11,929 (41%)
RV dysfunction (N = 12,714) 505 (21%) 2,503 (24%)
PAP levels > 50 mm Hg (N = 8,148) 290 (22%) 2,277 (33%)
TAPSE < 16 mm (N = 4,564) 120 (14%) 717 (19%)
Helical CT-scan findings,
Subsegmental 146 (4.3%) 576 (3.4%)
Segmental 628 (18%) 2,451 (14%)
More central 1,563 (46%) 7,904 (46%)
Not reported 1,074 (31%) 6,099 (36%)
Blood tests,
Anemia 1,631 (28%) 9,696 (34%)
Abnormal platelet count 369 (6.3%) 1,653 (5.7%)
CrCl levels 30-60 mL/min 116 (2.0%) 11,467 (40%)
CrCl levels < 30 mL/min 21 (0.36%) 2,208 (7.7%)
Raised troponin levels (N = 15,781) 576 (24%) 4,959 (37%)
BNP levels > 100 pg/ml (N = 2,722) 156 (44%) 1,629 (69%)
Table 1. Clinical characteristics of the patients, according to age.
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Discussion
The risk for PE progressively increases with the patient’s age. However, young patients are not uncommon, with 
one in every 6 cases in our cohort (17%) being aged <50 years. These patients had fewer co-morbidities, different 
risk factors, and different signs or symptoms at baseline compared with those aged ≥50 years. The 30-day mortal-
ity rate in our patients <50 years was low (1.43%) compared with the rate of 7.4% observed in the entire sample9. 
Proportion (%)
Patients 
(n = 5,822)
Died 
(n = 83) Event rate (%)
PESI22
Low risk 87.2 5,074 34 0.7
High risk 12.8 748 49 6.6
sPESI23
Low risk 59.4 3,459 10 0.3
High risk 40.6 2,363 73 3.1
Shock Index26
Low risk 70.9 4,126 32 0.8
High risk 21.1 1,406 50 3.6
GPS21
Low risk 89.6 5,214 40 0.8
High risk 10.4 608 43 7.1
Prognostic Algorithm24
Low risk 58 3,376 7 0.2
High risk 42 2,446 76 3.1
PREP25
Low risk 95.9 5,584 66 1.2
High risk 4.1 238 17 7.1
RIETE score27
Low risk 48.6 2,828 8 0.3
High risk 51.4 2,994 75 2.5
Table 2. Comparison of risk-class-specific 30-day all-cause mortality in different prognosis tools.
Sensitivity Specificity PPV NPV Accuracy AUC
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
PESI22 59.0 (48.5–69.6) 87.8 (87–88.7) 6.6 (4.8–8.3) 99.3 (99.1–99.6) 87.4 (86.6–88.3) 0.73 (0.67–0.80)
sPESI23 88 (81–95) 60.1 (58.8–61.4) 3.1 (2.4–3.8) 99.7 (99.5–99.9) 60.5 (59.2–61.8) 0.74 (0.70–0.78)
Shock Index26 61 (50.4–71.5) 75.1 (74–76.3) 3.6 (2.6–4.5) 99.2 (99–99.5) 74.9 (73.8–76.1) 0.68 (0.62–0.74)
GPS21 51.8 (41.1–62.6) 90.2 (89.4–90.9) 7.1 (5–9.1) 99.2 (99–99.5) 89.6 (88.8–90.4) 0.71 (0.64–0.78)
Prognostic 
Algorithm 24 91.6 (85.6–97.5) 58.7 (57.4–60) 3.1 (2.4–3.8) 99.8 (99.6–99.9) 59.1 (57.9–60.4) 0.75 (0.71–0.79)
PREP25 20.5(11.8–29.2) 96.2 (95.7–96.7) 7.1 (3.9–10.4) 98.8 (98.5–99.1) 95.1 (94.5–95.6) 0.58 (0.51–0.65)
RIETE score27 90.4 (84–96.7) 49.1 (47.8–50.4) 2.5 (2–3.1) 99.7 (99.5–99.9) 49.7 (48.4–51) 0.70 (0.65–0.74)
Table 3. Accuracy of the prediction rule to predict 30-day mortality in different prognosis tools.
30-day PE-related mortality 30-day major bleeding 30-day VTE recurrences
(n = 31) (n = 45) (n = 63)
N (%) N (%) N (%)
PESI22
Low risk 14 (45.2%) 29 (64.4%) 40 (63.5%)
High risk 17 (54.8%) 16 (35.6%) 23 (36.5%)
sPESI23
Low risk 5 (16.1%) 16 (35.6%) 22 (34.9%)
High risk 26 (83.9%) 29 (64.4%) 41 (65.1%)
Shock Index26
Low risk 12 (38.7%) 26 (57.8%) 39 (62.9%)
High risk 19 (61.3%) 19 (42.2%) 23 (37.1%)
GPS21
Low risk 18 (58.1%) 35 (77.8%) 45 (71.4%)
High risk 13 (41.9%) 10 (22.2%) 18 (28.6%)
Prognostic Algorithm24
Low risk 3 (9.7%) 15 (33.3%) 21 (33.3%)
High risk 28 (90.3%) 30 (66.7%) 42 (66.7%)
PREP25
Low risk 26 (83.9%) 42 (93.3%) 59 (93.7%)
High risk 5 (16.1%) 3 (6.7%) 4 (6.4%)
RIETE score27
Low risk 4 (12.9%) 12 (26.7%) 20 (31.8%)
High risk 27 (87.1%) 33 (73.3%) 43 (68.3%)
Table 4. Thirty-day PE related mortality, major bleeding and VTE recurrences of different prognosis tools.
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Despite these favorable figures, tools to identify low-risk patients should be sensitive and efficient. An improved 
identification of patients at risk and the use of accurate prognostic tools may pave the way to optimized manage-
ment strategies (i.e., drug selection, optimal dosing, treatment settings), ultimately reducing mortality rates. The 
current study compared seven distinct prognostic tools in the same patient cohort. Our main results indicated 
that sPESI, RIETE, and the Prognostic Algorithm scores were the most efficient tools to identify PE patients aged 
<50 years at low risk of death within the first 30 days. Notably, these three tools also had the highest sensitivity 
in the prediction of 7- and 90-day all-cause mortality, 30-day PE-related mortality, 30-day major bleeding, and 
30-day VTE recurrences.
Prognostic tools to identify low-risk patients with PE need to have the highest overall sensitivity and neg-
ative predictive value. Most of the tools examined in our study were effective and associated with a low event 
rate in patients considered at low risk. One important prerequisite is the definition of an incidence limit for a 
specific outcome that should be clinically relevant9. The correct identification of low-risk patients is paramount 
in real-life clinical practice. Tools characterized by a low incidence of events in the low-risk group identifies a 
smaller proportion of patients, being more effective but less efficient. In our study, tools with the higher propor-
tion of patients considered to be at low-risk were PREP, Geneva, and PESI, although their sensitivity was low. The 
selection of the best prognostic tool in a specific population is crucial to identify subjects at low risk that may be 
safely discharged home or managed in an outpatient setting. Although 30-day all-cause mortality was overall 
low in patients aged <50 years, the social, psychological, and economic impact of such deaths is not negligible. 
In 2017, the HOPPE score has been specifically developed to identify low-risk patients31. It is characterized by 
a good sensitivity (96–99%) and negative predictive value (95–96%) in the prediction of 30-day mortality. The 
HOPPE score consists of five ordinal variables (scored as 1, 2, or 3 points, respectively), as follows: systolic blood 
pressure values (>120, 100 to 119, <99 mmHg), diastolic blood pressure values (>80, 65 to 79, <64 mmHg), 
heart rate (<80, 81 to 100, > 101 beats/min), arterial partial pressure of oxygen (>80, 60 to 79, <59 mmHg), and 
modified electrocardiographic score (<2, 2 to 4, >4). The following modified electrocardiographic score with 
adjusted variables and point values is used: tachycardia: 2 points; incomplete right bundle branch block: 1 point; 
complete right bundle branch block: 3 points; T-wave inversion in V1 to V3: 4 points; S1Q3T3: 4 points. The 
HOPPE score finally identifies three prognostic groups, as follows: low-risk: 0–6 points; intermediate-risk: 7–10 
points; high-risk: 11–15 points. Although Subramanian and co-workers31 reported a short-term mortality of 0% 
(95% CI: 0–0.8%) in the low-risk group, the authors maintained that prospective validation of the HOPPE score 
is required before its implementation in clinical practice. Assessment of other tools or biomarkers may lead to the 
development of a more efficient model while maintaining a high sensitivity in the detection of low-risk patients.
The sPESI, RIETE, and Prognostic Algorithm scores are based on 6, 11, and 10 variables, respectively. The similar 
performances of the scores may be explained by the fact that five items are shared (Supplement Table 2) – including 
cancer, heart failure, pulse ≥110 beats per minute, systolic blood pressure <100 mmHg, and arterial blood oxygen sat-
uration <90%. The Prognostic Algorithm and sPESI also have age in common, whereas the Prognostic Algorithm and 
RIETE score share common chronic renal disease. For the sake of simplicity, the use of sPESI may be recommended. 
One of the most interesting findings was that PESI, a consistently validated tool, did not perform well in this patient 
population. Although patients deemed at low risk according to PESI had a low 30-day mortality rate (0.7%; 95% CI: 
0.5–0.9%), the sensitivity of the tool was low as well (59%; 95% CI: 48.5–69.6%). We speculate that this may stem from 
the influence of patient’s age on the score calculation. Accordingly, age is treated as a quantitative variable in PESI.
This work has several limitations. First, the design of RIETE does not randomize patients to different strategies 
or drugs, although quality-control audits are periodically implemented. We believe that our registry may provide 
relevant real-life data in a large number of patients observed outside the rigorous and controlled conditions of 
clinical trials. As such, it may be helpful to identify risk factors for clinical outcomes in an unselected patient 
population. Second, it is likely that patients who died early after PE (i.e., within 2–3 days) were not included in 
7-day all-cause mortality 30-day all-cause mortality 90-day all-cause mortality
(n = 38) (n = 83) (n = 148)
N (%) N (%) N (%)
PESI22
Low risk 17 (44.7%) 34 (41%) 60 (40.5%)
High risk 21 (55.3%) 49 (59%) 88 (59.5%)
sPESI23
Low risk 4 (10.5%) 10 (12.1%) 12 (8.1%)
High risk 34 (89.5%) 73 (88%) 136 (91.9%)
Shock Index26
Low risk 11 (29%) 32 (39%) 64 (44.1%)
High risk 27 (71.1%) 50 (61%) 81 (55.9%)
GPS21
Low risk 21 (55.3%) 40 (48.2%) 71 (48%)
High risk 17 (44.7%) 43 (51.8%) 77 (52%)
Prognostic Algorithm24
Low risk 2 (5.3%) 7 (8.4%) 9 (6.1%)
High risk 36 (94.7%) 76 (91.6%) 139 (93.9%)
PREP25
Low risk 30 (79%) 66 (79.5%) 126 (85.1%)
High risk 8 (21.1%) 17 (20.5%) 22 (14.9%)
RIETE score27
Low risk 3 (7.9%) 8 (9.6%) 8 (5.4%)
High risk 35 (92.1%) 75 (90.4%) 140 (94.6%)
Table 5. Seven, 30 and 90-day all-cause mortality of different prognosis tools.
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the cohort (because of lack of informed consent or death in emergency room). Third, the attribution of deaths to 
PE may be difficult owing to the lack of a validated definition based on broadly accepted criteria. Although causes 
of death were investigated by a thorough review of medical records, an overestimation of PE-related mortality 
cannot be ruled out32.
This study has two strengths. First, we simultaneously analyzed seven different prognostic tools in a large pop-
ulation of over 5,000 patients. This approach overcomes the caveats of heterogeneity in meta-analyses or propen-
sity scores matching. Second, this study evaluated not only 30-day all-cause mortality but also other short-term 
complications of PE (i.e., PE-related death, VTE recurrences, and bleedings).
conclusion
We compared seven prognostic tools to identify which was the most sensitive to identify patients aged <50 years 
with acute PE at low risk for 30-day mortality. The most performing tools were sPESI, RIETE, and Prognostic 
Algorithm. Because the mortality rates in our population were low, more efficient tools or biomarkers are required 
to improve the prognostic categorization of this patient group. Compared with elderly cases, PE patients aged <50 
years have a different profile, with less co-morbidities, different risk factors, and different signs and symptoms.
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